Haemonetics (HAE) Misses Q4 EPS by 21c, Revenues Beat; Offers FY22 EPS Guidance Above Consensus
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $76.19 +1.59%
Revenue Growth %: +2.3%
Financial Fact:
Provision for income taxes: 3M
Today's EPS Names:
CCEL, FEIM, PLG, More
Revenue Growth %: +2.3%
Financial Fact:
Provision for income taxes: 3M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q4 EPS of $0.46, $0.21 worse than the analyst estimate of $0.67. Revenue for the quarter came in at $225 million versus the consensus estimate of $222.98 million.
GUIDANCE:
Haemonetics sees FY2022 EPS of $2.60-$3.00, versus the consensus of $2.56.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Occidental Petroleum releases Q2 2026 earnings considerations
- Citi Adds Four Names to Catalyst Call List
- Goldman Sachs reports global fund inflows for week of July 8
Create E-mail Alert Related Categories
Corporate News, Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
